Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A direct comparison of divalent metal-ion transporter (DMT1) and hinokitiol, a potential small molecule replacement.

Garrick MD, Garrick LM, Zhao L, Collins JF, Soukup J, Ghio AJ.

Biometals. 2019 Oct;32(5):745-755. doi: 10.1007/s10534-019-00207-2. Epub 2019 Jul 31.

2.

Impact of a structured, group-based running programme on clinical, cognitive and social function in youth and adults with complex mood disorders: a 12-week pilot study.

Keating LE, Becker S, McCabe K, Whattam J, Garrick L, Frey BN, Sassi RB, McKinnon MC.

BMJ Open Sport Exerc Med. 2019 May 21;5(1):e000521. doi: 10.1136/bmjsem-2019-000521. eCollection 2019.

3.

Effects of a 12-week running programme in youth and adults with complex mood disorders.

Keating LE, Becker S, McCabe K, Whattam J, Garrick L, Sassi RB, Frey BN, McKinnon MC.

BMJ Open Sport Exerc Med. 2018 Jun 15;4(1):e000314. doi: 10.1136/bmjsem-2017-000314. eCollection 2018.

4.

A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese.

Wolff NA, Garrick MD, Zhao L, Garrick LM, Ghio AJ, Thévenod F.

Sci Rep. 2018 Jan 9;8(1):211. doi: 10.1038/s41598-017-18584-4.

5.

Athletes Rated as Poor Single-Leg Squat Performers Display Measurable Differences in Single-Leg Squat Biomechanics Compared With Good Performers.

Garrick LE, Alexander BC, Schache AG, Pandy MG, Crossley KM, Collins NJ.

J Sport Rehabil. 2018 Nov 1;27(6):546-553. doi: 10.1123/jsr.2016-0208. Epub 2018 Oct 13.

PMID:
29140159
6.

Acceptability of the Fitbit in behavioural activation therapy for depression: a qualitative study.

Chum J, Kim MS, Zielinski L, Bhatt M, Chung D, Yeung S, Litke K, McCabe K, Whattam J, Garrick L, O'Neill L, Goyert S, Merrifield C, Patel Y, Samaan Z.

Evid Based Ment Health. 2017 Nov;20(4):128-133. doi: 10.1136/eb-2017-102763. Epub 2017 Oct 22. Erratum in: Evid Based Ment Health. 2018 May;21(2):76.

7.

Behavioral activation group therapy for reducing depressive symptoms and improving quality of life: a feasibility study.

Samaan Z, Dennis BB, Kalbfleisch L, Bami H, Zielinski L, Bawor M, Litke K, McCabe K, Whattam J, Garrick L, O'Neill L, Tabak TA, Simons S, Chalmers S, Key B, Vanstone M, Xie F, Guyatt G, Thabane L.

Pilot Feasibility Stud. 2016 Apr 29;2:22. eCollection 2016.

8.

A pragmatic pilot randomized trial to investigate the effectiveness of behavioural activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: the BRAVE pilot trial protocol.

Samaan Z, Litke K, McCabe K, Dennis B, Whattam J, Garrick L, O'Neill L, Tabak TA, Simons S, Chalmers S, Key B, Vanstone M, Xie F, Guyatt G, Thabane L.

Pilot Feasibility Stud. 2015 Nov 10;1:39. eCollection 2015.

9.

Mitochondria represent another locale for the divalent metal transporter 1 (DMT1).

Wolff NA, Garrick LM, Zhao L, Garrick MD, Thévenod F.

Channels (Austin). 2014;8(5):458-66. doi: 10.4161/19336950.2014.956564.

10.

Evidence for mitochondrial localization of divalent metal transporter 1 (DMT1).

Wolff NA, Ghio AJ, Garrick LM, Garrick MD, Zhao L, Fenton RA, Thévenod F.

FASEB J. 2014 May;28(5):2134-45. doi: 10.1096/fj.13-240564. Epub 2014 Jan 21.

PMID:
24448823
11.

Divalent metal transporter 1 (Dmt1) mediates copper transport in the duodenum of iron-deficient rats and when overexpressed in iron-deprived HEK-293 cells.

Jiang L, Garrick MD, Garrick LM, Zhao L, Collins JF.

J Nutr. 2013 Dec;143(12):1927-33. doi: 10.3945/jn.113.181867. Epub 2013 Oct 2.

13.

Isoform specific regulation of divalent metal (ion) transporter (DMT1) by proteasomal degradation.

Garrick MD, Zhao L, Roth JA, Jiang H, Feng J, Foot NJ, Dalton H, Kumar S, Garrick LM.

Biometals. 2012 Aug;25(4):787-93. doi: 10.1007/s10534-012-9522-1. Epub 2012 Feb 7.

14.

Calcium-channel blockers do not affect iron transport mediated by divalent metal-ion transporter-1.

Mackenzie B, Shawki A, Ghio AJ, Stonehuerner JD, Zhao L, Ghadersohi S, Garrick LM, Garrick MD.

Blood. 2010 May 20;115(20):4148-9. doi: 10.1182/blood-2010-03-274738. No abstract available.

15.

Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.

Vera MD, Lundquist JT 4th, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5. doi: 10.1016/j.bmcl.2010.02.099. Epub 2010 Mar 3.

PMID:
20236823
16.

Cellular iron transport.

Garrick MD, Garrick LM.

Biochim Biophys Acta. 2009 May;1790(5):309-25. doi: 10.1016/j.bbagen.2009.03.018. Epub 2009 Apr 1. Review.

PMID:
19344751
17.

Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.

Hauze DB, Chengalvala MV, Cottom JE, Feingold IB, Garrick L, Green DM, Huselton C, Kao W, Kees K, Lundquist JT 4th, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel J, Pelletier JC.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1986-90. doi: 10.1016/j.bmcl.2009.02.043. Epub 2009 Feb 13.

PMID:
19251413
18.

Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.

Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nuñez MT, Garrick MD, Raisman-Vozari R, Hirsch EC.

Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18578-83. doi: 10.1073/pnas.0804373105. Epub 2008 Nov 14.

19.

2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor.

Pelletier JC, Chengalvala M, Cottom J, Feingold I, Garrick L, Green D, Hauze D, Huselton C, Jetter J, Kao W, Kopf GS, Lundquist JT 4th, Mann C, Mehlmann J, Rogers J, Shanno L, Wrobel J.

Bioorg Med Chem. 2008 Jul 1;16(13):6617-40. doi: 10.1016/j.bmc.2008.05.024. Epub 2008 May 11.

PMID:
18511284
20.

Induction of arachidonate 12-lipoxygenase (Alox15) in intestine of iron-deficient rats correlates with the production of biologically active lipid mediators.

Collins JF, Hu Z, Ranganathan PN, Feng D, Garrick LM, Garrick MD, Browne RW.

Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G948-62. doi: 10.1152/ajpgi.00274.2007. Epub 2008 Feb 7.

21.

Loss of rapid transferrin receptor recycling due to a mutation in Sec15l1 in hbd mice.

Garrick MD, Garrick LM.

Biochim Biophys Acta. 2007 Feb;1773(2):105-8. Epub 2006 Oct 4.

22.

Lung injury after ozone exposure is iron dependent.

Ghio AJ, Turi JL, Madden MC, Dailey LA, Richards JD, Stonehuerner JG, Morgan DL, Singleton S, Garrick LM, Garrick MD.

Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L134-43. Epub 2006 Aug 11.

23.

Comparison of mammalian cell lines expressing distinct isoforms of divalent metal transporter 1 in a tetracycline-regulated fashion.

Garrick MD, Kuo HC, Vargas F, Singleton S, Zhao L, Smith JJ, Paradkar P, Roth JA, Garrick LM.

Biochem J. 2006 Sep 15;398(3):539-46.

24.

DMT1: which metals does it transport?

Garrick MD, Singleton ST, Vargas F, Kuo HC, Zhao L, Knöpfel M, Davidson T, Costa M, Paradkar P, Roth JA, Garrick LM.

Biol Res. 2006;39(1):79-85.

25.

Iron homeostasis in the lung.

Ghio AJ, Turi JL, Yang F, Garrick LM, Garrick MD.

Biol Res. 2006;39(1):67-77. Review.

26.

Divalent metal transporter-1 decreases metal-related injury in the lung.

Ghio AJ, Piantadosi CA, Wang X, Dailey LA, Stonehuerner JD, Madden MC, Yang F, Dolan KG, Garrick MD, Garrick LM.

Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L460-7. Epub 2005 May 20.

27.

Computer-identified nuclear localization signal in exon 1A of the transporter DMT1 is essentially ineffective in nuclear targeting.

Kuo HC, Smith JJ, Lis A, Zhao L, Gonsiorek EA, Zhou X, Higgins DM, Roth JA, Garrick MD, Garrick LM.

J Neurosci Res. 2004 May 15;76(4):497-511.

PMID:
15114622
28.

Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat.

Ferguson CJ, Wareing M, Delannoy M, Fenton R, McLarnon SJ, Ashton N, Cox AG, McMahon RF, Garrick LM, Green R, Smith CP, Riccardi D.

Kidney Int. 2003 Nov;64(5):1755-64.

29.

DMT1: a mammalian transporter for multiple metals.

Garrick MD, Dolan KG, Horbinski C, Ghio AJ, Higgins D, Porubcin M, Moore EG, Hainsworth LN, Umbreit JN, Conrad ME, Feng L, Lis A, Roth JA, Singleton S, Garrick LM.

Biometals. 2003 Mar;16(1):41-54. Review.

PMID:
12572663
30.

Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat.

Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, Dolan KG, Haile DJ, Beard JL, Connor JR.

J Neurosci Res. 2001 Dec 15;66(6):1198-207.

PMID:
11746453
31.

Cellular distribution of iron in the brain of the Belgrade rat.

Burdo JR, Martin J, Menzies SL, Dolan KG, Romano MA, Fletcher RJ, Garrick MD, Garrick LM, Connor JR.

Neuroscience. 1999;93(3):1189-96.

PMID:
10473284
32.

Evidence for and consequences of chronic heme deficiency in Belgrade rat reticulocytes.

Garrick MD, Scott D, Kulju D, Romano MA, Dolan KG, Garrick LM.

Biochim Biophys Acta. 1999 Mar 8;1449(2):125-36.

33.

Non-transferrin-bound iron uptake in Belgrade and normal rat erythroid cells.

Garrick LM, Dolan KG, Romano MA, Garrick MD.

J Cell Physiol. 1999 Mar;178(3):349-58.

PMID:
9989781
34.

Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport.

Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC.

Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1148-53.

35.

Iron supplementation moderates but does not cure the Belgrade anemia.

Garrick M, Scott D, Walpole S, Finkelstein E, Whitbred J, Chopra S, Trivikram L, Mayes D, Rhodes D, Cabbagestalk K, Oklu R, Sadiq A, Mascia B, Hoke J, Garrick L.

Biometals. 1997 Apr;10(2):65-76.

PMID:
9210290
36.

Transferrin and the transferrin cycle in Belgrade rat reticulocytes.

Garrick MD, Gniecko K, Liu Y, Cohan DS, Garrick LM.

J Biol Chem. 1993 Jul 15;268(20):14867-74.

37.

Iron distribution in Belgrade rat reticulocytes after inhibition of heme synthesis with succinylacetone.

Garrick LM, Gniecko K, Liu Y, Cohan DS, Grasso JA, Garrick MD.

Blood. 1993 Jun 15;81(12):3414-21.

PMID:
8507877
38.

Ferric-salicylaldehyde isonicotinoyl hydrazone, a synthetic iron chelate, alleviates defective iron utilization by reticulocytes of the Belgrade rat.

Garrick LM, Gniecko K, Hoke JE, al-Nakeeb A, Ponka P, Garrick MD.

J Cell Physiol. 1991 Mar;146(3):460-5.

PMID:
2022700
39.
40.

Tissue iron deposition in untransfused beta-thalassemic mice.

Garrick LM, Strano-Paul LA, Hoke JE, Kirdani-Ryan LA, Alberico RA, Everett MM, Bannerman RM, Garrick MD.

Exp Hematol. 1989 Jun;17(5):423-8.

PMID:
2714422
41.

Differential synthesis of beta-major and beta-minor globin proteins in murine erythroleukemia cells is regulated at the transcriptional level.

Ganguly S, Skoultchi AI, Garrick MD, Garrick LM, Campbell AS, Alter BP.

J Biol Chem. 1988 Mar 5;263(7):3216-9.

42.

Diminished acquisition of iron by reticulocytes from mice with hemoglobin deficit.

Garrick LM, Edwards JA, Hoke JE, Bannerman RM.

Exp Hematol. 1987 Jul;15(6):671-5.

PMID:
3595766
43.

Post-synthetic modification in vivo of the major hemoglobin beta chain in the rat.

Garrick LM, Chu ML, Rusnak-Smalley P, Garrick MD.

Hemoglobin. 1987;11(5):497-510.

PMID:
3429247
44.

Hemoglobin deficit: an inherited hypochromic anemia in the mouse.

Bannerman RM, Garrick LM, Rusnak-Smalley P, Hoke JE, Edwards JA.

Proc Soc Exp Biol Med. 1986 May;182(1):52-7.

PMID:
3960859
45.

Functional properties of human adult hemoglobin specifically modified at the alpha-amino groups of the beta chains with D-glucose 6-phosphate.

Chiou SH, Garrick LM, McDonald MJ.

Biochemistry. 1982 Jan 5;21(1):13-20. No abstract available.

PMID:
7059573
46.

Structural and functional studies of hemolysates from genetically selected high and low level DPG rat strains.

McDonald MJ, Turci SM, Bunn HF, Garrick LM, Garrick MD, Brewer GJ.

Prog Clin Biol Res. 1981;55:215-24. No abstract available.

PMID:
7291191
47.

Structural analysis of the minor human hemoglobin components: Hb AIa1, Hb AIa2 and Hb AIb.

Garrick LM, McDonald MJ, Shapiro R, Bleichman M, McManus M, Bunn HF.

Eur J Biochem. 1980 May;106(2):353-9.

48.

Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation.

Bunn HF, Shapiro R, McManus M, Garrick L, McDonald MJ, Gallop PM, Gabbay KH.

J Biol Chem. 1979 May 25;254(10):3892-8. No abstract available.

49.

Nonenzymatic glycosylation of human hemoglobin at multiple sites.

Shapiro R, McManus M, Garrick L, McDonald MJ, Bunn HF.

Metabolism. 1979 Apr;28(4 Suppl 1):427-30.

PMID:
122295
50.

Deficiency of globin messenger RNA in reticulocytes of the Belgrade rat.

Chu ML, Garrick LM, Garrick MD.

Biochemistry. 1978 Nov 28;17(24):5128-33. No abstract available.

PMID:
728393

Supplemental Content

Loading ...
Support Center